Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025


BOSTON, Jan. 21, 2025 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced the presentation of latest data from its Phase I/II CLINCH study ongoing in China and Australia evaluating ATN-022 (CLDN18.2 antibody-drug conjugate [ADC]) in patients with advanced or metastatic gastric cancer at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2025 (ASCO GI 2025).

Details of the Poster Presentation:

ATN-022 (also known as ATG-022, CLDN18.2 antibody-drug conjugate)

Title: Safety and Preliminary Efficacy of ATG-022 in Patients with Advanced/Metastatic Gastric Cancer (CLINCH)

Abstract Number: 456 

Session: Poster Session A: Cancers of Esophagus and Stomach and Other Gastrointestinal Cancers

Presenter: Jinfeng Ma  Shanxi Cancer Hospital

Date: Thursday, January 23, 2025

Time: 11:30 AM - 1:00 PM (Pacific time)

           3:30 AM - 5:00 AM, January 24, 2025 (Beijing time)

About ATN-022

ATN-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, pancreatic and other cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATN-022, for gastric and pancreatic cancers.

Data from the ongoing CLINCH study of ATN-022 has shown promising clinical efficacy in gastric cancer patients with various levels of CLDN18.2 expression. The efficacy already observed across all levels of CLDN18.2 expression in patients with gastric cancer suggests that ATN-022 holds the promise as a competitive treatment option.

About Antennova

Antennova, a Delaware corporation and a subsidiary of Antengene (HKEX: 6996), is a clinical-stage biotech company specialized in developing innovative therapeutics that target the critical biological mechanisms that enable cancers to evade and resist treatment by current drugs. Antennova is developing a pipeline of oncology candidates that can potentially enhance the effectiveness of standard therapies.

Forward-Looking Statements

The forward-looking statements made in this document relate only to the events or information as of the date on which the statements are made in this document. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this document completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this document, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this document. Any of these intentions may alter in light of future development.

For more information, please contact:

Investor Relations
Email: [email protected]

SOURCE Antennova


These press releases may also interest you

at 16:41
Chef&Nutri was born out of the need to encourage healthier living. Focused on the ingestion of nutritionally complete, sustainable and functional foods, based in Bahia, the company is expanding its operations to the Southeast, Midwest and South, in...

at 13:27
Joint Announcement of the Teslin Tlingit Council, Government of Yukon, and Government of Canada Today, the Teslin Tlingit Council, the Honourable Gary Anandasangaree, Minister of Crown-Indigenous Relations and Northern Affairs, and the Government of...

at 08:00
On Saturday February 8th at 12 noon, the Grey Bruce, Brampton Caledon and Greater Toronto health coalitions, local chapters of the Ontario Health Coalition, will gather outside Minister of Health Sylvia Jones' constituency office to oppose and expose...

at 03:01
From February 6 to 9, 2025, the HICC Pet brand is showcasing its groundbreaking grooming and healthcare products at the Hong Kong Convention and Exhibition Centre during the Pet Show Hong Kong 2025. Known as a leader in pet healthcare, HICC Pet...

at 02:36
Report on how AI is driving market transformation - The global senior living market  size is estimated to grow by USD 130.9 billion from 2025-2029, according to Technavio. The market is estimated to grow at a CAGR of  5.8%  during the forecast...

7 fév 2025
Report with the AI impact on market trends - The global healthcare services market size is estimated to grow by USD 6.26 trillion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 8.73% during the forecast period....



News published on and distributed by: